Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma
The Journal of Pathology · 2023-11 · 261 (3) · 349-360
DOI: 10.1002/path.6197 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 05.09.2023. Verfasst von Rami S Vanguri und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Biomarkers, Tumor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue‐based immune biomarkers of clinical benefit to ICIs using multiplex immunofluorescence and to integrate these findings with previously identified peripheral blood biomarkers of response. Fifty‐five pretreatment and 12 paired on‐treatment UC specimens were identified from patients treated with nivolumab with or without ipilimumab. Whole tissue sections were stained with a 12‐plex mIF panel, including CD8, PD‐1/CD279, PD‐L1/CD274, CD68, CD3, CD4, FoxP3, TCF1/7, Ki67, LAG‐3, MHC‐II/HLA‐DR, and pancytokeratin+SOX10 to identify over three million cells. Immune tissue densities were compared to progression‐free survival (PFS) and best overall response (BOR) by RECIST version 1.1. Correlation coefficients were calculated between tissue‐based and circulating immune populations. The frequency of intratumoral CD3 + LAG‐3 + cells was higher in responders compared to nonresponders ( p = 0.0001). LAG‐3 + cellular aggregates were associated with response, including CD3 + LAG‐3 + in proximity to CD3 + ( p = 0.01). Exploratory multivariate modeling showed an association between intratumoral CD3 + LAG‐3 + cells and improved PFS independent of prognostic clinical factors (log HR −7.0; 95% confidence interval [CI] −12.7 to −1.4), as well as established biomarkers predictive of ICI response (log HR −5.0; 95% CI −9.8 to −0.2). Intratumoral LAG‐3 + immune cell populations warrant further study as a predictive biomarker of clinical benefit to ICIs. Differences in LAG‐3 + lymphocyte populations across the intratumoral and peripheral compartments may provide complementary information that could inform the future development of multimodal composite biomarkers of ICI response. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
ORCID-Profile: Rami S Vanguri, James W Smithy, Hikmat Al-Ahmadie
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Vanguri, R. S., Smithy, J. W., Li, Y., Zhuang, M., Maher, C. A., Aleynick, N., Peng, X., Al-Ahmadie, H., Funt, S. A., Rosenberg, J. E., Iyer, G., Bajorin, D., Mathews, J. C., Nadeem, S., Panageas, K. S., Shen, R., Callahan, M. K., & Hollmann, T. J. (2023). Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology, 261(3), 349-360. https://doi.org/10.1002/path.6197
Vancouver
Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, et al. Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology. 2023;261(3):349-360. doi:10.1002/path.6197
BibTeX
@article{Vanguri2023,
author = {Vanguri, Rami S and Smithy, James W and Li, Yanyun and Zhuang, Mingqiang and Maher, Colleen A and Aleynick, Nathaniel and Peng, Xiyu and Al-Ahmadie, Hikmat and Funt, Samuel A and Rosenberg, Jonathan E and Iyer, Gopa and Bajorin, Dean and Mathews, James C and Nadeem, Saad and Panageas, Katherine S and Shen, Ronglai and Callahan, Margaret K and Hollmann, Travis J},
title = {Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma},
journal = {The Journal of Pathology},
year = {2023},
volume = {261},
number = {3},
pages = {349--360},
doi = {10.1002/path.6197}
}
EUVIMED